CDK4 and neoplasm: Bolstered by strong preclinical evidence and careful consideration of molecular determinants of sensitivity, novel inhibitors may be well‐positioned to overcome CDK4/6i resistance, induce synthetic lethality in genomically unstable tumours and boost immunogenicity and sensitivity to immunotherapeutics, either as monotherapy or combined with CDK4/6i, DDR agents or immune checkpoint inhibitors, respectively.